News and Announcements
Dr Martin Cross Appointed Non-Executive Director at Oncosil
- Published February 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) is pleased to announce the appointment of Mr Lawrence Gozlan as an independent Non-executive Director of the Company, effective from today. Mr Gozlan is a highly experienced and successful biotechnology industry professional, with particular expertise in investment management and corporate advice in the life science sector.
Mr Gozlan is currently a Director of Prana Biotechnology (ASX: PBT), a Director of Ausbiotech Ltd and a number of private healthcare companies. He holds a Bachelor of Science with Honours in microbiology and immunology from the University of Melbourne.
OncoSil Medical chairman Martin Rogers said:
“On behalf of the board of directors it is with great pleasure that we welcome the appointment of Lawrence Gozlan as a non-exec director. His proven experience and track record as a biotech investment manager will be invaluable to the Company, and we are confident his input and contribution will further strengthen the board as we continue to unlock value for investors.”
OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical’s lead product is OncoSil™ with the first target indication being pancreatic cancer.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
